Aptamer:toxin conjugates that specifically target prostate tumor cells

被引：239

作者：

Chu, Ted C.

Marks, John W., III

Lavery, Laura A.

Faulkner, Sarah

Rosenblum, Michael G.

Ellington, Andrew D.

Levy, Matthew ^{[1
]}

机构：

[1] Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunopharmacol & Targeted Therapy, Houston, TX 77030 USA

来源：

CANCER RESEARCH | 2006年 / 66卷 / 12期

关键词：

D O I：

10.1158/0008-5472.CAN-05-4583

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

We have used RNA aptamer:gelonin conjugates to target and specifically destroy cells overexpressing the known cancer biomarker prostate-specific membrane antigen (PSMA). Aptamer:toxin conjugates have an IC50 of 27 nmol/L and display an increased potency of at least 600-fold relative to cells that do not express PSMA. The aptamer not only promotes uptake into target cells but also decreases the toxicity of gelonin in non-target cells. These results validate the notion that "escort aptamers" may be useful for the treatment of specific tumors expressing unique antigen targets.

引用

收藏

页码：5989 / 5992

页数：4

相关论文

共 20 条

[1]

BETTER M, 1994, J BIOL CHEM, V269, P9644

[2]

Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels - Selective targeting of endothelial regulatory protein pigpen [J].

Blank, M ;

Weinschenk, T ;

Priemer, M ;

Schluesener, H .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) :16464-16468

[3]

RETRACTED: Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase (Retracted Article) [J].

Cerchia, L ;

Ducongé, F ;

Pestourie, C ;

Boulay, J ;

Aissouni, Y ;

Gombert, K ;

Tavitian, B ;

de Franciscis, V ;

Libri, D .

PLOS BIOLOGY, 2005, 3 (04) :697-704

[4]

Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates [J].

Chu, TC ;

Shieh, F ;

Lavery, LA ;

Levy, M ;

Richards-Kortum, R ;

Korgel, BA ;

Ellington, AD .

BIOSENSORS & BIOELECTRONICS, 2006, 21 (10) :1859-1866

[5]

A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment [J].

Daniels, DA ;

Chen, H ;

Hicke, BJ ;

Swiderek, KM ;

Gold, L .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) :15416-15421

[6]

Oligonucleotide aptamers that recognize small molecules [J].

Famulok, M .

CURRENT OPINION IN STRUCTURAL BIOLOGY, 1999, 9 (03) :324-329

[7]

Nanopartide-aptamer bioconjugates: A new approach for targeting prostate cancer cells [J].

Farokhzad, OC ;

Jon, SY ;

Khademhosseini, A ;

Tran, TNT ;

LaVan, DA ;

Langer, R .

CANCER RESEARCH, 2004, 64 (21) :7668-7672

[8]

Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration - Phase II study results [J].

Fish, G ;

Haller, JA ;

Ho, AC ;

Klein, M ;

Loewenstein, J ;

Martin, D ;

Orth, D ;

Rosen, RB ;

Sanislo, S ;

Schwartz, SD ;

Singerman, LJ ;

Williams, G ;

Adamis, AP ;

Blumenkranz, M ;

Goldberg, M ;

Gragoudas, ES ;

Miller, JW ;

Yannuzzi, L ;

Guyer, DR ;

O'Shaughnessy, D ;

Patel, S .

OPHTHALMOLOGY, 2003, 110 (05) :979-986

[9]

Escort aptamers: a delivery service for diagnosis and therapy [J].

Hicke, BJ ;

Stephens, AW .

JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (08) :923-928

[10]

Jayasena SD, 1999, CLIN CHEM, V45, P1628